Lisa Cook sues Trump over firing attempt, emergency hearing set
Raymond (NSE:RYMD) Dwek, a director at United Therapeutics Corp (NASDAQ:UTHR), a pharmaceutical company with an impressive 89% gross profit margin and perfect Piotroski Score of 9 according to InvestingPro, recently executed a series of stock transactions. On April 14, 2025, Dwek sold 3,000 shares of the company’s common stock at a price of $285.16 per share, totaling approximately $855,480. This sale was part of a pre-arranged trading plan under Rule 10b5-1.
In addition to the sale, Dwek also exercised stock options to acquire 3,000 shares at an exercise price of $175.43 per share. Following these transactions, Dwek holds 1,750 shares of United Therapeutics common stock directly.
In other recent news, United Therapeutics Corporation reported its fourth-quarter 2024 earnings, revealing a shortfall in both earnings per share (EPS) and revenue compared to forecasts. The company posted an EPS of $6.19, below the expected $6.68, and revenue reached $735.9 million, slightly under the anticipated $739.92 million. Despite these misses, United Therapeutics achieved record annual revenue growth for the third consecutive year, with key products like Tyvaso and Orenitram showing strong revenue increases of 19% and 28%, respectively.
Goldman Sachs analyst Chris Shibutani adjusted the company’s stock price target to $293 from the previous $302, maintaining a Neutral rating. This revision followed a decline in United Therapeutics’ shares after its fourth-quarter results, which were in line with expectations but fell short of higher anticipated performance. Challenges for Tyvaso, including a 4% sequential decline and competitive pressures from potential market entries, contributed to this outlook. United Therapeutics did not provide financial guidance, consistent with its standard practice, and while further share repurchases could occur, no new plans were announced.
The company anticipates its first UKidney transplant around mid-2025, which could attract media attention and define commercial opportunities. Additionally, the outcomes of the IPF trials, TETON-2 and TETON-1, are seen as critical, with Shibutani expressing caution and a probability of success at 50%. The adjusted price target was influenced by a modest reduction in Tyvaso forecasts and increased research and development spending.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.